Compare
Strata Critical Medical, Inc. vs Omada Health, Inc. vs GeneDx Holdings Corp. vs Vsee Health, Inc.
| Latest fiscal year | Strata Critical Medical, Inc. SRTA | Omada Health, Inc. OMDA | GeneDx Holdings Corp. WGS | Vsee Health, Inc. VSEE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $197.14M | $260.21M | $427.54M | $14.62M |
| Revenue growth (YoY) | +34.3% | +53.2% | +40.0% | +40.3% |
| Gross margin | 20.9% | 65.7% | 69.7% | 50.3% |
| Operating margin | -11.3% | -4.6% | -3.1% | -65.6% |
| Net margin | 21.0% | -4.9% | -4.9% | -100.6% |
| Net income | $41.35M | -$12.78M | -$21.02M | -$14.71M |
| EPS (Diluted) | $0.50 | -$0.35 | -$0.73 | -$0.73 |
| Operating cash flow | -$48.91M | $18.25M | $33.28M | -$3.45M |
| Free cash flow | -$58.51M | $16.93M | $14.26M | -$3.48M |
| Cash & equivalents | $30.97M | $222.04M | $105.00M | $5.27M |
| Total assets | $325.47M | $305.41M | $523.71M | $22.41M |
| Total liabilities | $46.40M | $75.73M | $215.53M | $16.96M |
| Shareholders' equity | $279.07M | $229.68M | $308.18M | $5.45M |
| Return on year-end equity | 14.8% | -5.6% | -6.8% | -269.8% |
| Shares outstanding | n/a | 58.43M | 29.25M | 33.19M |
Revenue, most recent five fiscal years
| Fiscal year | Strata Critical Medical, Inc. | Omada Health, Inc. | GeneDx Holdings Corp. | Vsee Health, Inc. |
|---|---|---|---|---|
| Latest | $197.14M Ended 2025-12-31 | $260.21M Ended 2025-12-31 | $427.54M Ended 2025-12-31 | $14.62M Ended 2025-12-31 |
| 1 year earlier | $146.82M Ended 2024-12-31 | $169.80M Ended 2024-12-31 | $305.45M Ended 2024-12-31 | $10.42M Ended 2024-12-31 |
| 2 years earlier | $225.18M Ended 2023-12-31 | $122.78M Ended 2023-12-31 | $202.57M Ended 2023-12-31 | $5.77M Ended 2023-12-31 |
| 3 years earlier | $146.12M Ended 2022-12-31 | n/a | $234.69M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $212.19M Ended 2021-12-31 | n/a |